#1 Clinical Trials Search in Europe

Spiramycin

Spiramycin, a macrolide antibiotic, has been the subject of several clinical trials investigating its effectiveness in treating various parasitic infections. These trials have primarily focused on its use in treating cryptosporidiosis in AIDS patients and preventing congenital toxoplasmosis in pregnant women. The studies aim to evaluate the safety, efficacy, and optimal dosing of spiramycin in different patient populations.

Table of Contents

What is Spiramycin?

Spiramycin, also known by its brand name Rovamycine®, is a macrolide antibiotic. Antibiotics are medications used to treat various bacterial and parasitic infections. Spiramycin has been studied for its effectiveness in treating several conditions, particularly those caused by parasites[1].

Conditions Treated with Spiramycin

Spiramycin has been investigated for its potential in treating the following conditions:

  • Cryptosporidiosis: A parasitic infection that causes diarrhea, especially in people with weakened immune systems[1][2]
  • Toxoplasmosis: Another parasitic infection that can be particularly dangerous for pregnant women and their unborn children[3]

Spiramycin has been studied for its potential in treating diarrhea related to AIDS (Acquired Immunodeficiency Syndrome), particularly when caused by a parasite called Cryptosporidium. This condition, known as cryptosporidial diarrhea, can be severe in people with weakened immune systems[1].

Research has shown mixed results regarding the effectiveness of spiramycin for this condition. Some reports suggest it may help improve symptoms in some patients. However, one study found no significant difference between spiramycin and a placebo (an inactive substance). It’s important to note that the absorption of spiramycin can be significantly decreased when taken with food, which may have affected the results of some studies[1].

Spiramycin in Preventing Congenital Toxoplasmosis

Spiramycin has been used in France as a preventive treatment for congenital toxoplasmosis. This is a condition where a pregnant woman becomes infected with the Toxoplasma gondii parasite and passes it to her unborn child. The infection can cause serious damage to the baby’s eyes and nervous system[3].

In France, spiramycin is often prescribed to pregnant women who have been newly infected with toxoplasmosis. However, its effectiveness in preventing transmission to the fetus has not been conclusively proven. Ongoing research is comparing spiramycin to other antiparasitic drugs (pyrimethamine and sulfadiazine) to determine which treatment is more effective in preventing mother-to-child transmission of toxoplasmosis[3].

How Spiramycin is Administered

The way spiramycin is given can vary depending on the condition being treated and the specific study or treatment protocol. Here are some examples:

  • For AIDS-related diarrhea: In one study, spiramycin was given intravenously (through a vein)[1]
  • For preventing congenital toxoplasmosis: In a French study, spiramycin was given orally (by mouth) at a dose of 1 gram three times a day[3]

Ongoing Research and Clinical Trials

Spiramycin continues to be the subject of research to better understand its effectiveness and safety for various conditions. Some ongoing areas of study include:

  • Comparing spiramycin to other treatments for preventing congenital toxoplasmosis[3]
  • “Compassionate use” studies for treating chronic diarrhea due to cryptosporidiosis in patients with compromised immune systems[2]
  • Its role in treating congenital toxoplasmosis in infants, often in combination with other medications[4]

It’s important to note that the use of spiramycin may vary depending on the country and specific medical situation. Always consult with a healthcare professional for the most up-to-date and personalized information about using spiramycin or any other medication.

Aspect Details
Main Conditions Studied Cryptosporidiosis in AIDS patients, Congenital toxoplasmosis
Administration Method Oral, Intravenous (in some trials)
Typical Dosage 1g three times daily (for oral administration)
Treatment Duration Varies: 15-21 days for cryptosporidiosis, throughout pregnancy for toxoplasmosis prevention
Comparison Treatments Placebo, Pyrimethamine + Sulfadiazine combination
Key Outcomes Measured Safety, efficacy, mother-to-child transmission rates, tolerance in mothers and neonates
Special Considerations Absorption may be affected by food intake, prenatal diagnosis and monitoring required in pregnancy studies

FAQ

  • What is spiramycin used for in clinical trials? Spiramycin is being studied for treating cryptosporidial diarrhea in AIDS patients and preventing congenital toxoplasmosis in pregnant women who have been infected with Toxoplasma gondii.
  • How is spiramycin administered in these trials? In the trials, spiramycin is typically administered orally. For example, in one study, patients received spiramycin 1g three times daily.
  • Are there any side effects associated with spiramycin use? While specific side effects are not detailed in the provided information, the trials mention monitoring for clinical and biological tolerance. Treatment may be stopped or changed in case of toxicity.
  • How long does spiramycin treatment usually last in these trials? Treatment duration varies depending on the condition being studied. For cryptosporidiosis, treatment periods of 15 to 21 days were mentioned. For toxoplasmosis prevention during pregnancy, treatment may continue throughout the pregnancy.
  • Is spiramycin being compared to other treatments in these trials? Yes, in some trials, spiramycin is being compared to other treatments. For example, in a toxoplasmosis prevention trial, spiramycin is being compared to a combination of pyrimethamine and sulfadiazine.

Ongoing Clinical Trials on Spiramycin

  • Study on Reducing Antibiotic Use in Severe COPD Exacerbation with Amoxicillin, Cefotaxime, and Ciprofloxacin for Patients on Mechanical Ventilation or Oxygen Therapy

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

Glossary

  • Spiramycin: A macrolide antibiotic used in clinical trials to treat certain parasitic infections, particularly cryptosporidiosis and toxoplasmosis.
  • Cryptosporidiosis: A parasitic infection that can cause severe diarrhea, especially in people with weakened immune systems, such as AIDS patients.
  • Toxoplasmosis: An infection caused by the parasite Toxoplasma gondii, which can be particularly dangerous if contracted during pregnancy.
  • Congenital toxoplasmosis: Toxoplasmosis infection passed from a mother to her unborn child, potentially causing damage to the eyes, nervous system, and other organs.
  • Macrolide antibiotic: A class of antibiotics that work by preventing bacteria from making proteins, thereby stopping their growth.
  • Seroconversion: The development of detectable antibodies in the blood directed against an infectious agent.
  • Placebo: An inactive substance used in clinical trials to compare the effects of a drug against no treatment.
  • Pyrimethamine: An antiparasitic medication often used in combination with other drugs to treat toxoplasmosis.
  • Sulfadiazine: An antibiotic often used in combination with pyrimethamine to treat toxoplasmosis.
  • Amniocentesis: A prenatal test where a small amount of amniotic fluid is removed from the sac surrounding the fetus for testing.

References

  1. https://clinicaltrials.gov/study/NCT00000980
  2. https://clinicaltrials.gov/study/NCT00002062
  3. https://clinicaltrials.gov/study/NCT01189448
  4. https://clinicaltrials.gov/study/NCT00004317